Home » Authors » Brady Huggett

Articles by Brady Huggett

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Feb. 25, 2003

By Brady Huggett

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Feb. 25, 2003

By Brady Huggett

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Feb. 24, 2003

By Brady Huggett

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Feb. 24, 2003

By Brady Huggett

Biogen's Amevive Shot Down In Europe; Approval Years Away

Feb. 21, 2003

By Brady Huggett

SomaLogic Raises $19.5M To Develop Proteomics Products

Feb. 21, 2003

By Brady Huggett

Biogen's Amevive Shot Down In Europe; Approval Years Away

Feb. 21, 2003

By Brady Huggett

SomaLogic Raises $19.5M To Develop Proteomics Products

Feb. 21, 2003

By Brady Huggett

BattellePharma Raises $22M To Develop Inhalation Program

Feb. 20, 2003

By Brady Huggett

BattellePharma Raises $22M To Develop Inhalation Program

Feb. 20, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 3, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 3, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Radiopharma Telix acquires FAP-targeting agents for bladder cancer
BioWorld
Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.